March 2020

Press Release
Publication of Clinical Data Confirms RepliCel’s Treatment for Androgenic Alopecia Effective in Men and Women
A randomized, placebo-controlled, double-blinded clinical study in Japan testing a one-time injection of RCH-01 in...
Press Release
Japan's Regulatory Agency, PMDA, Clears RepliCel Life Sciences to Proceed to Final Consultation for Tendon and Skin Cell Therapy Products
RepliCel completes the second of three formal consultation reviews with Japan's Pharmaceuticals and Medical Devices Agency in...
Press Release
Japan’s Patent Office Issues RepliCel Two New Patents for its Regenerative Medicine Technologies
Timely patent-grants support next steps in RepliCel’s First-in-Japan strategyVANCOUVER, BC, CANADA – 10 March 2020 – RepliCel Life...
Press Release
Production of Dermal Injectors Delayed by China Work Stoppage Affecting Critical Component
Production of Dermal Injectors Delayed by China Work Stoppage Affecting Critical ComponentInitial run of commercial-grade...

The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.